News - Pharmaceutical, Hematology

Filter

Current filters:

PharmaceuticalHematology

Popular Filters

1 to 25 of 45 results

JAMA study shows bone marrow transplants can reverse sickle cell disease

03-07-2014

Bone marrow transplants can reverse severe sickle cell disease in adults, according to new data published…

HematologyPharmaceuticalResearchUSA

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

EHA 2013: GSK announces results of Phase III PETIT2 study of eltrombopag

16-06-2014

UK pharma major GlaxoSmithKline announced the results from the Phase III PETIT2 study evaluating the…

eltrombopagEuropeGlaxoSmithKlineHealth Medical PharmaHematologyItalyMajorMedicinePharmaceuticalResearchThrombocytopenic purpura

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

16-06-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, announced Phase…

EuropeHematologyJanssen-CilagLymphomaPharmaceuticalResearchVelcade

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

16-06-2014

Among companies presenting results from across the board at the European Hematology Association annual…

Beta-thalassemiaCelgeneEuropeHematologyPharmaceuticalpomalidomideResearchVidaza

Novartis’ Glivec could lose half patient population in China to generics

Novartis’ Glivec could lose half patient population in China to generics

03-06-2014

Hematologists in China estimate that Glivec (imatinib) from Swiss drug major Novartis will lose nearly…

Blast phase CMLChemistryChinaChronic phase CMLGlivecHealth Medical PharmaHematologyMajorMarkets & MarketingNovartisPharmaceutical

Vifor’s Ferinject reduces need for other anemia treatment

03-06-2014

Vifor Pharma, a part of Switzerland-based Galenica Group which develops pharmaceutical products for the…

EuropeFerinjectHematologyPharmaceuticalResearchVifor Pharma

FDA approves new indication for Bayer's Kogenate

12-05-2014

The US Food and Drug Administration has approved a new indication for German drug major Bayer's Kogenate…

BayerHematologyKogenate FSPharmaceuticalRegulationUSA

Preventative treatment with NovoEight reduces bleeding in hemophilia A

Preventative treatment with NovoEight reduces bleeding in hemophilia A

12-05-2014

Danish insulin giant Novo Nordisk has announced new Phase III interim data from its guardianT2 trial…

Coagulation systemDenmarkGuardianT2HematologyInsulin giantNovo NordiskNovoEightPharmaceuticalResearchVIII (rFVIII)World Congress

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

17-04-2014

US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

21-03-2014

US biotech firm Biogen Idec has announced that Health Canada has approved Alprolix for the control and…

AlprolixBiogen IdecCanadaHematologyPharmaceuticalRegulation

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

Bayer to invest 500 million-euro-plus in hemophilia products manufacturing in Germany

12-03-2014

German pharma major Bayer revealed yesterday that it plans an investment of more than 500 million euros…

BayerFinancialGermanyHematologyNorthern EuropePharmaceuticalProduction

Cumberland Pharma acquires Vaprisol from Astellas

03-03-2014

USA-based Cumberland Pharmaceuticals says it has acquired from the US subsidiary of Japan’s Astellas…

Astellas PharmaCumberland PharmaceuticalsHematologyLicensingNorth AmericaPharmaceuticalUSAVaprisol

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

US orphan designation for OPKO's longer-acting clotting Factor VIIa-CTP

03-03-2014

The US Food and Drug Administration has granted orphan drug designation to US drugmaker OPKO Health’s…

HematologyNorth AmericaOPKO HealthPharmaceuticalRare diseasesUSA

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

Positive Ph III results with Bayer’s long-acting recombinant factor VIII product BAY94-9027

18-02-2014

Germany’s Bayer has released positive results from the PROTECT VIII trial evaluating the company’s…

BAY94-9027BayerHematologyPharmaceuticalResearch

Australia’s CSL posts solid half-year results

Australia’s CSL posts solid half-year results

13-02-2014

Australian blood products and vaccine maker CSL reported a 3% rise in net profit to $646 million (all…

CSL LimitedFinancialHematologyPharmaceuticalVaccines

La Jolla Pharma gains hepcidin agonists rights from INSERM

12-02-2014

San Diego, USA-based drug developer La Jolla Pharmaceutical has entered into an exclusive worldwide license…

HematologyLa Jolla PharmaceuticalLicensingPharmaceuticalResearch

$20 million milestones for MacroGenics from Servier

$20 million milestones for MacroGenics from Servier

06-02-2014

Servier, France’s largest privately‐held pharmaceutical company, has exercised its exclusive option…

FinancialHematologyLicensingMacroGenicsMGD006OncologyPharmaceuticalServier

Baxter restructures deal with Xenetic Biosciences

31-01-2014

USA-based Baxter International has restructured its ongoing agreement with Xenetic Biosciences for the…

BAX 826Baxter InternationalHematologyLicensingPharmaceuticalResearchXenetic Biosciences

FDA cites insufficient information in response to AMAG’s Feraheme application

FDA cites insufficient information in response to AMAG’s Feraheme application

23-01-2014

US drug company AMAG Pharmaceuticals (Nasdaq: AMAG) has received a complete response letter from the…

AMAG PharmaceuticalsFerahemeHematologyNephrology and HepatologyPharmaceuticalRegulationUSA

Swedish company Dilaforette announces Sobi’s Christina Herder as new CEO

22-01-2014

Swedish drug development company Dilaforette has named Christina Herder as its new chief executive.

BoardroomDilaforetteHematologyNorthern EuropePharmaceuticalSobi

Galena Biopharma acquires Mills Pharmaceuticals

14-01-2014

US drugmaker Galena Biopharma revealed that it has acquired Mills Pharmaceuticals, which has the worldwide…

AnagrelideGalena BioPharmaHematologyMergers & AcquisitionsMills PharmaceuticalsPharmaceutical

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

Japan to investigate Novartis promotion of Diovan; US allegation over Exjade

10-01-2014

Swiss drug major Novartis faced two problems yesterday, when the Japanese Ministry of Health Labor and…

Asia-PacificCardio-vascularDiovanExjadeHematologyLegalMarkets & MarketingNorth AmericaNovartisPharmaceuticalUSA

1 to 25 of 45 results

Back to top